Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that results from autoimmune-mediated destruction of the myelin sheath. Among the most prominent immunodiagnostic features of MS is the accumulation of B cell-secreted antibodies in the CNS and cerebrospinal f uid (CSF) . Observations that the number of B cells in CSF correlates positively with MS progression and that the CNS microenvironment in MS patients promotes B cell persistence and expansion also support B cell involvement (1) . Recent clinical f ndings demonstrate that B cell-targeted therapies profoundly mitigate disease activity in MS patients. Specif cally, clinical studies show that CD20 B celldepleting therapies signif cantly reduce the frequency of relapses and of new demyelinating lesions, and accumulating evidence suggests that immunotherapies that block immune-cell traf cking across the bloodbrain barrier (BBB) reduce disease activity in part by impeding B cell function (2) .
Although these observations indicate that B cells contribute to MS pathogenesis, little is known about the sites of B cell-af nity maturation that produce the putative pathogenic B cells or the mechanisms that regulate antigen-dependent selection and activation of the B cells that populate the CNS. In this issue of Science Translational Medicine, Palanichamy et al. By comparing the Ig-VH repertoire of cell-sorted peripheral B cell subsets to that of B cells in patient-matched CSF, the authors found that peripheral class-switched memory B cells and plasma cells have the greatest degree of sequence overlap with CSF B cells, whereas peripheral unswitched memory B cells and naïve B cells have the least. T us, it appears that antigen-experienced, and not naïve, B cells constitute the humoral immune axis that spans the peripheral blood and the CNS. Because B cells can dif erentiate into switched memory B cells and plasma cells only af er a productive germinal-center reaction, these f ndings support the emerging concept that MS pathology derives from successive rounds of CNS tissue damage, by which early antigen encounters generate autoreactive memory B cells, and subsequent antigen encounters activate memory B cells, resulting in B cell-mediated tissue destruction in the CNS (Fig. 1 ).
WHERE B CELLS MATURE IN MS
Where do these autoreactive B cells initially undergo af nity maturation? In order for the humoral immune system to develop af nitymatured antibody responses, B cells must traf c to germinal centers, where activation signals trigger prosurvival signals, somatic hypermutation, and antibody class-switching. Stern and colleagues (4) compared the immunoglobulin repertoires in sectioned MS brain tissues with those in patientmatched cervical lymph nodes that drain the brain so as to determine whether B cells associated with MS gain antigen experience in peripheral lymphoid tissues or within the CNS. T ey observe that B cell populations that contained sequences most closely resembling germline sequences-which they term "founder events"-are highly enriched in B cell lineages that span both tissues despite their low frequency. T is implies that B cell lineages with members in both the CNS and CLN are prone to undergo additional rounds of af nity maturation.
T e authors then examine lineage trees for the occurrence of founders within the CNS and cervical lymph nodes and found that ~90% of founders are present in the cervical lymph nodes. Although it is impossible to def nitively conclude where B cells f rst encounter antigen on the basis of sequence data alone, these results support a role for peripheral immunity in shaping the repertoire of CNS B cells and suggest that the initial antigen-dependent maturation of intercompartmental B cells occurs predominantly in the periphery. T is concept is supported by previous studies that identify neuronal-derived antigens in the cervical lymph nodes of MS patients (6). In some instances, the sequences of bicompartmental lineages that displayed a high number of mutations were present in the CNS tissues, and in other instances, they were present in the periphery. T is distribution of highly mutated sequences suggests a bidirectional exchange of B cells across the BBB and argues that af nity maturation can occur in both the CNS tertiary lymphoid structures and the cervical lymph nodes (Fig. 1) .
CLINIC AND QUESTIONS
T erapeutic agents that target immune function by inhibiting B cell traf cking might abrogate cross-compartmental B cell movement and activation and thereby provide benef t in MS. Two therapeutics currently being used to treat MS are natalizumab, a humanized monoclonal antibody that targets a cell adhesion molecule necessary for
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Daniel R. LuFOCUS immune cell movement across tissues, and FTY720, which binds to a G protein-coupled receptor thought to regulate immune cell movement into the circulation. But, additional research is needed to further def ne how these agents af ect B cell traf cking and B cell-mediated inf ammation. Bidirectional traf cking of B cells might also explain how therapies that deplete circulating B cells also reduce B cells in cerebral perivascular spaces (2, 7), which may be responsible for the therapeutic activity of such agents in MS.
T e fact that it is af nity-matured memory B cells that contribute to the immune continuum between the periphery and CNS has implications for MS pathogenesis. Because formation of memory B cells requires prior encounters with antigen and the successful completion of the germinal center reaction, the new f ndings (3, 4) suggest that aberrant exposure of myelin antigens, neuronal antigens, or microbial antigenic mimics to the immune system shapes the autoimmune response in MS patients (1) (8, 9) , but it is not known whether these antigens are targeted in all or only a subset of these patients. Both papers report an overrepresentation of certain IGHV4 germline segments, a f nding that suggests that selection of antibodies in MS is skewed toward particular antigen epitopes. Because MS is known to present with a diverse array of clinical features, improved classif cation of antibody-repertoire heterogeneity and specif city might enable current and future treatments to be more ef ectively targeted to relevant patient populations.
Although the sequencing approaches used by Palanichamy et al. (10) . Such methodologies will enable more comprehensive characterization of antibody repertoires in MS and other autoimmune diseases. Further, these nextgeneration technologies enable recombinant production of representative antibodies and thus identif cation of the antibodies' autoantigen targets, as well as assessment of their pathogenicity. Such characterization of representative antibodies will allow the "functional annotation" of antibody repertoires and thereby link the repertoires to autoimmune specif city and disease pathogenesis. 
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